Table 3

Mean values of VAS for pain where available

TendinopathyStudyVAS type (unspecified, at rest, at night, with activity)VAS scaleGTN groupPlacebo groupTreatment effect for pain
(VAS 2 − VAS 1) – (VAS 4 − VAS 3)
VAS baseline42 VAS longest follow-up42 VAS baseline (3)VAS longest follow-up (4)
Rotator cuff (acute)Berrazueta et al Unspecified0–107.1265.5−4.6Yes
Rotator cuffGiner-Pascual et al 33 Unspecified0–−2.4Yes
PatellarSteunebrink et al 35 With activity0–10 (reverse)−0.5*No
AchillesKane et al 30 Unspecified0–−0.1No
Lateral epicondylitisPaoloni et al 27 With activity0–−0.1No
Paoloni et al 31P†With activity0–40‡36343228.2+1.8No
Paoloni et al 31PAt rest0–40‡36353229.4+1.6No
Paoloni et al 31 At night0–40‡3231.83027.3+2.5No
Ozden et al 34 Unspecified0–−3.5Yes
  • The statistical significance column (p<0.05) denotes whether there was a significant benefit in VAS for pain with topical GTN versus placebo.

  • *Due to the reverse VAS scale used (0=worst pain and 10=no pain), our subtraction was also reverse, that is, (VAS 1 – VAS 2) – (VAS 3 – VAS 4).

  • †In this study, only the mean VAS values of the highest strength GTN (3.6 mg/24 hours) group are presented for all pain with activity, at rest and at night; however, the lowest strength GTN group did have significantly less pain with activity at follow-up compared with placebo.

  • ‡The VAS scale used is not stated in the article, but we assume based on the reported values and the previous article by the same group (were a VAS scale of 0–4 was used) that it is 0–40.

  • GTN, glyceryl trinitrate; VAS, visual analogue scale.